GlassScriptPhysician profile
Frederick Wade Lewis
NPI 1184738320
$1,750.93
in general payments reported to CMS, 2019-2025
10 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $15.08 · 2022: $429 · 2023: $339 · 2024: $362 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $861.55 | 2019-2025 | |
| Boston Scientific Corporation | $331.23 | 2019-2025 | General - Biliary Devices, Axios |
| Olympus America INC. | $184.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.76 | 2019-2023 | Entyvio |
| Celgene Corporation | $84.24 | 2022-2024 | Zeposia |
| Conmed Corporation | $38.34 | 2024 | Conmed Generators |
| Pfizer INC. | $37.46 | 2019 | |
| Gilead Sciences, INC. | $34.33 | 2024-2025 | |
| Amgen INC. | $24.07 | 2023 | Amjevita, Avsola |
| Ethicon US, LLC | $15.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.